

PRIOR AUTHORIZATION CRITERIA

BRAND NAME*
(generic)

ODACTRA
(house dust mite allergen extract)

Status: CVS Caremark® Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Odactra is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive *in vitro* testing for IgE antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or by positive skin testing to licensed house dust mite allergen extracts. Odactra is approved for use in persons 12 through 65 years of age.

Odactra is not indicated for the immediate relief of allergic symptoms.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed as immunotherapy for house dust mite (HDM)-induced allergic rhinitis
AND
 - The request is NOT for continuation of therapy
AND
 - The diagnosis has been confirmed by positive *in vitro* testing for IgE antibodies to *Dermatophagoides farinae* or *Dermatophagoides pteronyssinus* house dust mites, or positive skin testing to licensed house dust mite allergen extracts
AND
 - The patient does not have ANY of the following: A) Severe, unstable or uncontrolled asthma, B) History of any severe systemic allergic reaction, C) History of any severe local reaction after taking any sublingual allergen immunotherapy, D) History of eosinophilic esophagitis
AND
 - The requested drug is being prescribed by, or in consultation with, an allergist or immunologist
 - OR**
 - The request is for continuation of therapy
AND
 - The patient has achieved or maintained improvement in rhinoconjunctivitis symptoms (e.g., runny nose, stuffy nose, sneezing, itchy nose, gritty/itchy eyes, watery eyes), OR the patient had a reduction in use of allergy symptom-relieving medications (e.g., antihistamines, corticosteroids)

Duration of Approval (DOA):

- 1610-A: DOA: 12 months

REFERENCES

1. Odactra [package insert]. Hørsholm, Denmark: ALK-Abelló A/S; January 2023.
2. Lexicomp Online, Lexi-Drugs. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed January 02, 2024.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 01/02/2024).

Odactra PA Policy UDR 02-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423